Restoring Tacrolimus-Induced Impaired Barrier Function  by Aber, Cheryl & Kirsner, Robert S.
journal club
554 Journal of Investigative Dermatology (2011), Volume 131 © 2011 The Society for Investigative Dermatology
For the article: http://dx.doi.org/10.1038/jid.2010.344
QUESTIONS
1. What is tacrolimus, and how does it work?
2. What was the rationale for carrying out this study?
3. How did the investigators perform their study, and what were their results?
4. What were the conclusions and implications of the study?
Our bodies are equipped with a variety of mechanisms 
to optimize survival. A keratinized epidermis and the 
complex “brick and mortar” construction are first 
lines of defense against invading organisms. When 
the stratum corneum and epidermal architecture are 
disrupted, a second line of defense, the innate immune 
system, is upregulated. Previous studies have shown 
that topically applied tacrolimus slows restoration of 
the epidermal barrier following tape stripping and also 
reduces the innate immune reactivity, which ordinarily 
serves in antimicrobial defense (Kim et al., 2010).
Tacrolimus is used commonly for patients with atopic 
dermatitis (AD), which may involve barrier disrup-
tion, cutaneous infections, and downregulated innate 
immune reactivity (Howell, 2007). In randomized trials, tacrolimus improves the skin of patients with AD without 
increasing the frequency of bacterial infections. By contrast, viral skin infections have been reported to be increased 
(Ashcroft et al., 2005). Consequently, the effects of tacrolimus on the epidermal barrier may be important.
To examine mechanisms of tacrolimus-impaired barrier restoration, Jung et al. (2011, this issue) evaluated 
the role of IL-1 in the stimulation of barrier-function recovery. Working with both mice and human volun-
teers, these researchers demonstrated a role for IL-1α signaling in tacrolimus-induced permeability barrier 
dysfunction. Intracutaneous injection of IL-1α significantly improved barrier recovery of tacrolimus-treated 
murine skin; however, this improvement was not observed in transgenic mice that lacked the IL-1 recep-
tor. Interestingly, imiquimod, which induces IL-1α, accelerated barrier recovery in tacrolimus-treated skin, 
increased epidermal lipid production via upregulation of enzymes important in lipid synthesis, and increased 
mRNA levels of molecules involved in innate immunity—specifically, mouse β-defensin 3 and cathelin-related 
antimicrobial peptide. Through the following questions, we examine this paper in greater detail. For brief 
answers, please refer to the supplementary information online <http://www.nature.com/jid/journal/v131/n3/
suppinfo/jid2010431s1.html>
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